Surface Markers of Liver Cancer Stem Cells and Innovative Targeted-therapy Strategies for HCC

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 14

PMID 29434903

Citations 16

Authors

Lige Qiu

Hailiang Li

Sirui Fu

Xiaofang Chen

Ligong Lu

Affiliations

Soon will be listed here.

Abstract

Liver cancer stem cells (LCSCs) have important roles in the occurrence, development, recurrence, therapy resistance and metastasis of hepatocellular carcinoma (HCC). Therefore, intensive studies are undergoing to identify the mechanisms by which LCSCs contribute to HCC invasion and metastasis, and to design more efficient treatments for this disease. With continuous efforts in LCSC research over the years, therapies targeting LCSCs are thought to have great potential for the clinical treatment and prognosis of liver cancer. Novel LCSC surface markers are continuously discovered and several have been used in targeted therapies to reduce HCC recurrence, metastasis, and drug resistance following tumor resection. The present review describes the surface markers characterizing LCSCs and the recent progress in therapies targeting these markers, including antibodies and polypeptides.

Citing Articles

Implicating the cholecystokinin B receptor in liver stem cell oncogenesis.

Gay M, Drda J, Chen W, Huang Y, Yassin A, Duka T Am J Physiol Gastrointest Liver Physiol. 2024; 326(3):G291-G309.

PMID: 38252699 PMC: 11211039. DOI: 10.1152/ajpgi.00208.2023.

Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance.

Nairuz T, Mahmud Z, Manik R, Kabir Y Stem Cell Rev Rep. 2023; 19(6):1577-1595.

PMID: 37129728 DOI: 10.1007/s12015-023-10529-x.

Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies.

Pompili S, Vetuschi A, Sferra R, Cappariello A Front Oncol. 2022; 12:933675.

PMID: 35814444 PMC: 9259994. DOI: 10.3389/fonc.2022.933675.

The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers.

Jun S, Yoon H, Yoon J, Jeon S, Lee J, Halder D Cancers (Basel). 2021; 13(12).

PMID: 34208132 PMC: 8230774. DOI: 10.3390/cancers13122925.

Chronic alcohol exposure promotes HCC stemness and metastasis through -catenin/miR-22-3p/TET2 axis.

Chen D, Yan Y, Wang X, Li S, Liu Y, Yu D Aging (Albany NY). 2021; 13(10):14433-14455.

PMID: 34019487 PMC: 8202861. DOI: 10.18632/aging.203059.

References

Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim H . CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120(9):3326-39. PMC: 2929722. DOI: 10.1172/JCI42550. View

Chen J, Liu Q, Xiao J, Du J . EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA. Biomacromolecules. 2015; 16(6):1695-705. DOI: 10.1021/acs.biomac.5b00551. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Yao J, Zhang T, Ren J, Yu M, Wu G . Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep. 2009; 22(4):781-7. DOI: 10.3892/or_00000500. View

Schmelzer E, Reid L . EpCAM expression in normal, non-pathological tissues. Front Biosci. 2007; 13:3096-100. DOI: 10.2741/2911. View

Park H, Lee K, Lee S, Yoon M . Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol Biotechnol. 2011; 51(3):212-20. DOI: 10.1007/s12033-011-9458-7. View

Ma S, Chan K, Lee T, Tang K, Wo J, Zheng B . Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008; 6(7):1146-53. DOI: 10.1158/1541-7786.MCR-08-0035. View

Song W, Li H, Tao K, Li R, Song Z, Zhao Q . Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008; 62(8):1212-8. DOI: 10.1111/j.1742-1241.2008.01777.x. View

Lang J, Lan X, Liu Y, Jin X, Wu T, Sun X . Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts. Nucl Med Biol. 2015; 42(5):505-512. DOI: 10.1016/j.nucmedbio.2015.01.003. View

10.

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

11.

Ades E, Zwerner R, Acton R, Balch C . Isolation and partial characterization of the human homologue of Thy-1. J Exp Med. 1980; 151(2):400-6. PMC: 2185777. DOI: 10.1084/jem.151.2.400. View

12.

Munz M, Baeuerle P, Gires O . The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009; 69(14):5627-9. DOI: 10.1158/0008-5472.CAN-09-0654. View

13.

Ma S, Chan K, Hu L, Lee T, Wo J, Ng I . Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132(7):2542-56. DOI: 10.1053/j.gastro.2007.04.025. View

14.

Ashmun R, Look A . Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood. 1990; 75(2):462-9. View

15.

Skubitz A, Taras E, Boylan K, Waldron N, Oh S, Panoskaltsis-Mortari A . Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 2013; 130(3):579-87. PMC: 3906852. DOI: 10.1016/j.ygyno.2013.05.027. View

16.

Yamashita T, Forgues M, Wang W, Kim J, Ye Q, Jia H . EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5):1451-61. DOI: 10.1158/0008-5472.CAN-07-6013. View

17.

Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard G . Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2005; 24(3):506-13. DOI: 10.1634/stemcells.2005-0282. View

18.

Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D . Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. DOI: 10.1158/0008-5472.CAN-06-3126. View

19.

Schlesinger M, Yron I . Antigenic changes in lymph-node cells after administration of antiserum to thymus cells. Science. 1969; 164(3886):1412-3. DOI: 10.1126/science.164.3886.1412. View

20.

Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M . Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010; 52(6):872-9. DOI: 10.1016/j.jhep.2009.12.030. View